BioCentury
ARTICLE | Clinical News

Teverelix LA: Phase II data

May 16, 2005 7:00 AM UTC

In a U.K. Phase II trial, 2 intramuscular injections of 90 mg Teverelix LA suppressed testosterone to castration levels in 14 patients. After the first injection on day 1, suppression of testosterone ...